

cPLA₂ (C-20): sc-1724

BACKGROUND

Phospholipase A₂s (PLA₂s) constitute a family of esterases that hydrolyze the sn-2-acyl ester bond in glycerophospholipid molecules. These enzymes are generally calcium-dependent and have been found both intra- and extracellularly. By hydrolyzing the sn-2 bond in glycerophospholipids, PLA₂s release fatty acids. One such fatty acid, arachidonic acid, generates the substrates for the initiation of the arachidonic acid cascade that produces various eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes), many of which are potent mediators of inflammation. PLA₂s include both the relatively low molecular weight group I, group II and group V enzymes and the form known as cytoplasmic PLA₂ (cPLA₂). This form of PLA₂ is present in macrophages, and hydrolyzes the sn-2 fatty acyl ester bond of phospholipids to produce a free fatty acid and a lysophospholipid.

CHROMOSOMAL LOCATION

Genetic locus: PLA2G4A (human) mapping to 1q31.1; Pla2g4a (mouse) mapping to 1 G1.

SOURCE

cPLA₂ (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of cPLA₂ of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-1724 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

cPLA₂ (C-20) is recommended for detection of cytosolic PLA₂ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

cPLA₂ (C-20) is also recommended for detection of cytosolic PLA₂ in additional species, including equine, canine and bovine.

Suitable for use as control antibody for cPLA₂ siRNA (h): sc-29280, cPLA₂ siRNA (m): sc-35098, cPLA₂ shRNA Plasmid (h): sc-29280-SH, cPLA₂ shRNA Plasmid (m): sc-35098-SH, cPLA₂ shRNA (h) Lentiviral Particles: sc-29280-V and cPLA₂ shRNA (m) Lentiviral Particles: sc-35098-V.

Molecular Weight of cPLA₂: 85-114 kDa.

Positive Controls: NIH/3T3 whole cell lysate: sc-2210, HeLa whole cell lysate: sc-2200 or cPLA₂ (m): 293T Lysate: sc-119430.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



cPLA₂ (C-20): sc-1724. Western blot analysis of cPLA₂ expression in non-transfected: sc-117752 (A) and mouse cPLA₂ transfected: sc-119430 (B) 293T whole cell lysates.



cPLA₂ (C-20): sc-1724. Immunofluorescence staining of methanol-fixed HeLa cells showing cytoplasmic staining.

SELECT PRODUCT CITATIONS

1. Tzima, E., et al. 2000. Investigation of the relocation of cytosolic phospholipase A₂ and annexin V in activated platelets. *Thromb. Res.* 97: 421-429.
2. Cui, J.G., et al. 2007. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. *Neuroreport* 18: 115-119.
3. Zhang, S., et al. 2008. Expression of cytosolic phospholipase A₂ and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. *ORL J. Otorhinolaryngol. Relat. Spec.* 70: 242-248.
4. Herbert, S.P., et al. 2009. Activation of cytosolic phospholipase A₂-α as a novel mechanism regulating endothelial cell cycle progression and angiogenesis. *J. Biol. Chem.* 284: 5784-5796.
5. Regan-Klapisz, E., et al. 2009. Golgi-associated cPLA₂α regulates endothelial cell-cell junction integrity by controlling the trafficking of transmembrane junction proteins. *Mol. Biol. Cell* 20: 4225-4234.
6. Hastings, A.D., et al. 2009. Association with actin mediates the EGTA-resistant binding of cytosolic phospholipase A₂-α to the plasma membrane of activated platelets. *Cell Biol. Int.* 33: 83-91.
7. Moes, M.J., et al. 2011. Attachment of HeLa cells during early G₁ phase. *Histochem. Cell Biol.* 136: 399-411.
8. Tang, C., et al. 2010. A role for receptor-operated Ca²⁺ entry in human pulmonary artery smooth muscle cells in response to hypoxia. *Physiol Res.* 59: 909-918.
9. Moes, M.J., et al. 2011. Attachment of HeLa cells during early G₁ phase. *Histochem. Cell Biol.* 136: 399-411.



Try **cPLA₂ (4-4B-3C): sc-454** or **cPLA₂ (E-1): sc-376618**, our highly recommended monoclonal alternatives to cPLA₂ (C-20). Also, for AC, HRP, FITC, PE, Alexa Fluor[®] 488 and Alexa Fluor[®] 647 conjugates, see **cPLA₂ (4-4B-3C): sc-454**.